深圳微芯生物科技股份有限公司 关联交易管理制度 第一章 总则 第一条 为规范深圳微芯生物科技股份有限公司以下简称"公司")的关联交易行为, 保 护公司、股东和债权人的合法权益, 保证公司关联交易决策行为的公允性, 根 据《中华人民共和国公司法》《中华人民共和国证券法》《上海证券交易所科 创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等法律、法规和规范性文件以及《深圳微芯生物科技股份有限 公司章程》(以下简称"公司章程")的有关规定, 并结合公司具体情况制定本 制度。 第二章 关联方和关联交易 公司发生关联交易, 应当保证关联交易的合法性、必要性、合理性和公允性, 保持公司的独立性, 不得利用关联交易调节财务指标, 损害公司利益。 控股股东、实际控制人与公司发生关联交易, 应当遵循关联交易程序公平与实 质公平的原则, 并签署书面协议, 不得造成公司对其利益的输送。 第三条 关联交易的定义: 关联交易是指公司或者其合并报表范围内的子公司等其他 主体与公司关联方之间发生的交易, 包括以下交易和日常经营范围内发生的 可能引致资源或者义务转移的事项: 第二条 公司关联交易应当遵循 ...

1 第一条 为进一步完善深圳微芯生物科技股份有限公司(以下简称"公司")法人治理结 构, 明确总经理的职权、职责, 规范总经理的行为, 依据《中华人民共和国公 司法》(以下简称"《公司法》")和《深圳微芯生物科技股份有限公司章程》(以 下简称"公司章程"), 特制定本工作细则。 第二条 公司设总经理一名。 第三条 总经理对董事会负责, 组织实施董事会决议, 主持公司日常经营管理工作。 第四条 总经理由董事会决定聘任或者解聘。 第五条 总经理每届任期三年, 连聘可以连任。 第六条 总经理对董事会负责, 行使下列职权: (一) 主持公司的生产经营管理工作, 组织实施董事会决议, 并向董事会报 告工作; (二) 组织实施公司年度经营计划和投资方案; (三) 拟订公司内部管理机构设置方案; (四) 拟订公司的基本管理制度; (五) 制定公司的具体规章; (六) 提请董事会聘任或者解聘公司副总经理、财务负责人; (七) 决定聘任或者解聘除应由董事会决定聘任或者解聘以外的负责管理人 员; 第三章 职责及权限 2 深圳微芯生物科技股份有限公司 总经理工作细则 第一章 总则 第二章 总经理的职权 (八) 列席董事会会议; ( ...

深圳微芯生物科技股份有限公司 章程 二〇二五年十一月 | | | 深圳微芯生物科技股份有限公司 章程 | 则 . | | --- | | 营宗旨和范围 | | り . | | 股份发行 . | | 股份增减和回购 . | | 股份转让 . | | 东和股东会 . | | 股东的一般规定 . | | 控股股东和实际控制人 . | | 股东会的一般规定 . | | 股东会的召集 … | | 股东会的提案与通知 | | 股东会的召开 . | | 股东会的表决和决议 | | 事和董事会 | | 董事的一般规定 | | 董事公 … | | 独立董事 | | 董事会专门委员会 … | 第一章 总则 | 7 生于FF (以/)/人 | | --- | | 第二节 董事会 | | 第三节 独立董事 . | | 第四节 董事会专门委员会 | | 第六章 高级管理人员 | | 第七章 财务会计制度、利润分配和审计 | | 第一节 财务会计制度 . | | 第二节 内部审计 . | | 第三节 会计师事务所的聘任 | | 第八章 通知和公告 . | | 第一节 通知 . | | 第二节 公告 | | 第九章 合并、分立、增资、减资 ...

微芯生物公告，公司股东博奥生物及其一致行动人天府清源控股有限公司于2025年10月23日至2025年11 月19日期间，通过竞价交易和大宗交易方式合计减持公司股份482.95万股。博奥生物及其一致行动人合 计持有公司股份比例从10.00%减少至8.82%，权益变动触及1%刻度。本次权益变动为履行此前披露的减 持股份计划，不涉及资金来源，减持计划尚未实施完毕，信息披露义务人仍处于减持期。 ...

Core Insights - On November 19, Microchip Biotech executed a block trade of 811,000 shares, amounting to 20.3642 million yuan, which accounted for 8.23% of the total trading volume for the day [1] - The transaction price was 25.11 yuan, representing a 10% discount compared to the market closing price of 27.9 yuan [1] Summary by Category Trading Activity - The block trade involved a total of 811,000 shares at a price of 25.11 yuan per share [1] - The total transaction value reached 20.3642 million yuan [1] Market Impact - The executed trade price was 10% lower than the market closing price, indicating a significant discount [1] Institutional Participation - The trade was primarily conducted by institutional investors, with various buying and selling departments involved [2]

Group 1 - The report emphasizes the rapid development of China's innovative pharmaceuticals, highlighting that the number of clinical trials has reached a global leading position, with a significant increase in new drug approvals [3][5][7] - Chinese pharmaceutical companies are transitioning from a "fast follower" to an "innovation leader" model, actively engaging in cutting-edge fields such as ADC, bispecific antibodies, and mRNA vaccines, with a notable increase in the number of products in late-stage development [8][11][18] - The report identifies two main investment directions: the transformation of biotech companies into biopharma and the revaluation of traditional pharmaceutical companies during their innovation transition, suggesting specific companies to watch in both categories [3][4] Group 2 - China's integration into the global innovative drug value chain is deepening, with a growing number of global multi-center clinical trials led by Chinese companies, indicating a shift in the global drug development landscape [3][24] - The report notes that the contribution of Chinese companies to global clinical trials has significantly increased, with a projection of 1,903 innovative drug clinical trials registered in China by 2024 [7][24] - The report highlights the increasing competitiveness of Chinese companies in high-potential therapeutic areas, particularly in oncology, metabolic diseases, and autoimmune diseases, with substantial market shares in these segments [18][19] Group 3 - The report discusses the rising trend of BD (business development) transactions involving Chinese assets, with a notable increase in transaction amounts and numbers, indicating China's growing influence in the global pharmaceutical innovation landscape [33][44] - It highlights that the majority of license-out projects are now in early stages, reflecting the international interest in early-stage Chinese innovations, particularly in oncology and metabolic therapies [39][44] - The report points out that major multinational corporations (MNCs) are increasingly seeking next-generation blockbuster products from China to fill revenue gaps due to impending patent expirations [62][66]

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the development paths of innovative drugs and the role of AI in drug research and development [1][2] - Industry experts emphasized the need for Chinese pharmaceutical companies to shift from "follower" to "leader" by addressing unmet medical needs and leveraging innovative technologies [1][2] Group 1: Conference Highlights - The conference theme was "Bay Area Innovation, Navigating New Journeys," discussing key topics such as dual circulation development, accelerated technology transfer, and compliance in global expansion [1] - Notable speakers included industry leaders and experts, highlighting the importance of innovation and internationalization as core drivers for Chinese pharmaceutical companies [2] Group 2: Regulatory and Industry Perspectives - The Director of the Guangdong Provincial Drug Administration stressed the importance of drug quality and safety, urging companies to strengthen regulatory compliance and communication with authorities to avoid approval delays [1] - The conference aimed to inject new vitality into the biopharmaceutical industry in the Greater Bay Area and across China, promoting high-quality development and attracting talent and projects [1]

Core Insights - The seventh Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Innovation Conference was held in Guangzhou, focusing on the theme "Bay Area Innovation, Navigating New Journeys" [1] - Key topics discussed included the dual circulation development path for innovative drugs, acceleration of technology transfer, compliant global expansion, and the role of AI in empowering the entire drug development chain [1] Group 1 - The conference was co-hosted by the Guangdong Provincial Biopharmaceutical Innovation Technology Association and the Guangzhou Science and Technology Progress Foundation, with participation from various organizations including Boji Pharmaceutical Technology Co., Ltd. [1] - The event aimed to explore solutions for innovative drugs in the current complex environment, injecting new vitality and wisdom into the innovation development of the biopharmaceutical industry in the Greater Bay Area and nationwide [1] Group 2 - Notable attendees included prominent figures such as academician Zhong Nanshan, various directors from health authorities in Guangdong, Hong Kong, and Macau, and leaders from over 1,000 top scientists and industry leaders [2] - The conference provided a platform for discussing the future development and innovative practices in the biopharmaceutical sector within the Greater Bay Area [2]

Summary of Key Points Core Viewpoint - Microchip Biotech experienced significant trading activity on November 13, with a total of 9 transactions on the block trading platform, amounting to 1.181 million shares and a total transaction value of 30.7533 million yuan, indicating a discount of 13.63% compared to the closing price of the day [2]. Trading Activity - The average transaction price was 26.04 yuan, which is 13.63% lower than the closing price of 30.15 yuan on the same day [2]. - Institutional trading desks participated in 4 of the transactions, with a total transaction value of 13.1242 million yuan, resulting in a net purchase of 13.1242 million yuan [2]. - Over the past three months, Microchip Biotech has recorded a total of 10 block trades, with a cumulative transaction value of 34.4253 million yuan [2]. Stock Performance - The closing price of Microchip Biotech on November 13 was 30.15 yuan, reflecting a 3.04% increase, with a daily turnover rate of 3.21% and a total trading volume of 392 million yuan [2]. - The stock has seen a net outflow of 23.5728 million yuan in main capital for the day, and a cumulative decline of 1.12% over the past five days, with a total net outflow of 50.6034 million yuan [2]. Margin Trading Data - The latest margin financing balance for Microchip Biotech is 664 million yuan, which has decreased by 11.8255 million yuan over the past five days, representing a decline of 1.75% [2].

| 交易日期 | 证券简称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 卖出营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-11-13 | 微芯生物 | 688321 | 26.04 | 260.4 | 10 | 有限公司北京望祭 | 公司深圳章受准秀 | | 2025-11-13 | 微芯生物 | 688321 | 26.04 | 208.32 | 8 | 机构专用 | 公司深圳堂安海秀 | | 2025-11-13 | 微芯生物 | 688321 | 26.04 | 200.51 | 7.7 | 华泰证券股公营限 | 公司深圳景安温秀 | | 2025-11-13 | 微芯生物 | 688321 | 26.04 | 200.51 | 7.7 | 机构专用 | 公司深圳青年温泉 | | 交易日期 | 证券简称 | 证券代码 | | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 英出营业部 | | --- | --- | --- | --- | --- | -- ...